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Abstract 
Background: All international guidelines suggested that Tenofovir and Entecavir are the primary drugs at the first 
line therapy for the treatment of chronic hepatitis B (CHB). However, in Turkey these medications reimbursed at the 
second line therapy according to the Healthcare Implementation Notification. The aim of this study is to compare the 
cost effectiveness of oral antiviral treatment strategies in CHB for Turkey using lamuvidine, telbuvidine, entecavir, and 
tenofovir as medications.
Methods: The analysis was conducted using Markov models. The analysis scenarios based on first line treatment 
options with Lamuvidine, Telbuvidine, Entecavir, and Tenofovir as the medications. In the analysis, inadequate 
response or resistance after receiving 12 months of the treatment with Entecavir and Telbivudine were compared to 
the results found from switching from Entecavir to Tenofovir or from switching from Telbuvidine to Tenofovir. In addi-
tional, inadequate response or resistance after receiving 6 months of the treatment for Lamivudine was compared 
to the results found from switching from Lamivudine to Tenofovir. The study population included men and women, 
who were 40 years of age. The patients` compliance was estimated 100 % for all of the therapy options. The model 
duration was constructed to evaluate, treatment strategy duration of 40 years. The cost of medications, examinations/
follow-ups and complications were included in the model. Years of Potential Life Lost was used as the health out-
come. An incremental cost-effectiveness ratio analysis has been conducted.
Results and discussion: While the minimum years of life lost was found as 0.22 with tenofovir treatment in 5 years, 
treatment cost was calculated as 12,169 TL. These values were detected as 0.56 years and 7727 TL, 0.37 years and 
12,770 TL, respectively for lamuvidine and telbuvidine treatments. The maximum years of life lost and treatment cost 
was with lamuvidine treatment were detected as 1.60 years and 18,813 TL and, secondly 0.89 years and 24,007 TL for 
lamuvidine-tenofovir treatment during 10 years. The minimum years of life lost and cost are 0.54 year and 35,821 TL 
for tenofovir treatment during 10 years. The minimum years of life lost and cost were determined as 1.21 years and 
52,839 TL for tenofovir treatment strategy during 20 years. During 30 years period, tenofovir treatment was found to 
have the minimum years of life lost (1.73 years) and minimum cost (84,149 TL). When the results of 40 years period 
were analyzed, years of life lost and costs are 2.06 years and 119,604 TL, 2.13 years and 162,115 TL, 2.13 years and 
161,642 TL, 6.52 years and 147,245 TL, 3.20 years and 132,157 TL, 4.10 years and 151,059 TL and 3.05 years and 138,182 
TL for tenofovir, entecavir, entecavir-tenofovir, lamuvidine, lamuvidine-tenofovir, telbivudine and telbivudine-tenofovir.
Conclusions: In the model presented in this study, in cost effectiveness analysis about CHB treatments, Tenofovir was 
found to be one of the cost effective methods in comparison with other treatment strategies different time intervals. 
Beyond this achievement Tenofovir has shown to reduce cumulative treatment cost in first line CHB treatment when 
compared with regard to 40 year cumulative treatment cost.
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Tenofovir maintains the effective suppression of HBV 
DNA through 8  years of treatment with no evidence of 
TDF resistance in contrast to other agents [8]. In addi-
tion to the effective suppression of HBV DNA with a 
TDF treatment, there have been histological improve-
ments in a 5-year treatment both in cirrhotic and non-
cirrhotic CHB patients [9]. As Entecavir has a 1.2  % 
resistance potential in a naïve treatment group, Entecavir 
patients should also be closely monitored for resistance. 
In addition, in long-term use, the cumulative probabil-
ity of Entecavir resistance development in lamivudine-
refractory patients was reported to be as high as 57  % 
over 6  years of treatment [11]. In a 2-year Globe trial, 
it was shown that the Telbivudine resistance rates were 
25.1 % for HBeAg positive patients and 10.8 % for HBeAg 
negative patients. The M204I signature mutation was the 
primary basis for Telbivudine resistance, with secondary 
mutations detected at the L80, L180, and other codons. 
In vitro studies have shown that HBV with the M204I 
mutation remains sensitive to the nucleotide analogues 
adefovir, dipivoxil, and tenofovir [7].
Lamivudine has been approved in Turkey since 2000. 
For a long period of time, lamivudine was the only treat-
ment before Entecavir approval in 2006. Tenofovir and 
Telbivudine were approved in Turkey in 2007 and 2008, 
respectively. Based on the Globe [7] study’s results, a road 
map concept has been generated by the Social Security 
Institute [10]. From 2009 to 2015, Lamivudine and Tel-
bivudine was stratified as the first line treatment options 
for low viral loaded patients (HBV DNA <104 IU/mL). As 
a result, 2/3 of HBV patients had been treated with Lami-
vudine and Telbivudine. Tenofovir was only prescribed 
for high viral loaded patients (HBV DNA >104 IU/mL) or 
patients with a detectable HBV DNA level after 6 months 
of therapy with Lamivudine or Telbivudine.
This analysis compares Lamivudine, Telbivudine, Ente-
cavir, and Tenofovir, the oral antiviral agents used for first 
line CHB treatment according to the Health Application 




The Markov model was used in the present analysis. The 
Markov model is designed to include the entire disease 
whether the patients respond to therapy or not, compli-
cations develop in the case of irresponsiveness to ther-
apy, complications progress in years, and a follow up 
for the patients until death (Fig.  1). In the analysis sce-
narios, Lamivudine (3TC), Telbivudine (LdT), Entecavir 
Background
Hepatitis B is among the most common infectious dis-
eases worldwide. At least 2 billion individuals are esti-
mated to have been infected with the Hepatitis B virus 
(HBV), and 378 million individuals (6  % of the world’s 
population) are estimated to be chronic carriers world-
wide. Cirrhosis, hepatic failure, or hepatocellular can-
cer are known to develop in approximately 40  % of all 
chronic hepatitis B (CHB) cases [1, 2].
The prevalence of the hepatitis B surface antigen 
(HBsAg) was determined as 4.57 % according to a meta-
analysis conducted to investigate HBV epidemiology 
in Turkey. The confidence interval (CI) was determined 
as 3.58–5.76, and the estimated number of CHB cases 
was 3.3 million. This ratio increases to 9.8 % in the east-
ern part of Turkey. According to the epidemiologic data 
obtained between 1999 and 2009, while Hepatitis B prev-
alence is 3.23 % in the age group of 0–14 years, it is 5.77 % 
in the age group of 15–24 years. This ratio is 7.08 % in the 
25–34 age group, 6.93 % in the 35–44 age group, 6.13 % in 
the 45–54 age group, and 5.02 % in the 55–64 age group. 
Hepatitis B surface antigen (HBsAg) prevalence increases 
with age according to this study [3].
Oral antiviral treatment is the most convenient way to 
control and stabilize the CHB disease. The indications 
are generally the same for HBeAg positive and negative 
patients [4]. Treatment is usually based on assessing the 
combination of three criteria: serum HBV DNA values, 
ALT values, and the stage of the hepatic disease [4].
The goal of treatment for Chronic Hepatitis B is to pre-
vent the progression to cirrhosis, reducing the need for 
liver transplantation and improving the quality of life of 
the patient. Both national and international CHB treat-
ment guidelines reveal that HBV DNA should be strongly 
suppressed for achieving these goals. With the treat-
ment, the histopathological findings of the liver and the 
biochemical parameters are improved and the long-term 
complications of CBH are reduced as well [4].
Some current treatment guidelines, such as the Euro-
pean Association for the Study of the Liver (EASL), the 
American Association for the Study of Liver Diseases 
(AASLD) and the Asia Pacific Association for the Study 
of the Liver (APASL) recommend potent Oral Anti-viral 
(OAV) treatments as the first choice in initial therapy for 
achieving the specified goals [4–6]. In Turkey, changes 
have been made in Healthcare Reimbursement Rules to 
be aligned with International Hepatology Management 
and Treatment guidelines. Potent OAV treatments, such 
as Tenofovir and Entecavir, were approved to be used for 
a low viral loaded patient population in 2014 [8].
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(ETV), and Tenofovir (TDF) use was planned for first 
line therapy. Treatments that switched to Tenofovir from 
Entecavir (ETV- TDF) and to Tenofovir from Telbivu-
dine (LdT-TDF) in the case of an inadequate response or 
resistance development after 12 months or that switched 
to Tenofovir from Lamivudine (3TC-TDF) in the case of 
an inadequate response or responsiveness 6 months later 
were included in the analysis. A single strategy was also 
included during the model time in all molecules in tran-
sitional treatments. The resistance rates of the drugs and 
the estimated 5-year virologic response rates for each 
treatment were obtained from published studies.
Treatment population
The age for beginning treatment was 40  years, and the 
duration of treatment was 40  years, which is consist-
ent with the life expectancy. Of the patients, 50 % were 
assumed to be male and 50 % were assumed to be female 
in the Turkish population [8]. They were assumed to be 
100  % compliant to therapy. The HBeAg positivity rate 
was assumed to be 30  % [9]. The transition probabil-
ity between disease stages was taken from the analysis 
of Kanwal et al. [13]. (Table 1). Tables 2 and 3 show the 
response rates of CHB treatments in the model and the 
resistance rates. The rates of resistance developing dur-
ing the therapy and the cumulative resistance rates for 
the first 3 years of therapy were obtained from the data of 
the paper published by Marcellin et al., and the assump-
tions were used for the resistance rates after 3 years [11, 
12]. The resistance data of Entecavir treatment for the 
first 6  years were obtained from the study published by 
Tenney et al., and the assumptions were made for the fol-
lowing years [14]. The Lamivudine resistance data were 
calculated proportionally with the yearly resistance rates 
of the patients who had a high viral load for the fourth 
and the fifth years, and it was assumed to be half of the 
previous year for each year after the fifth year [15]. The 
Telbuvidin response data were obtained from the data 
of Zeuzem et al. and calculated proportionally with 3TC 
treatment at the third year and thereafter [16] (Table. 2, 
3).
The rates of response developing during therapy and 
the data were obtained from the paper published by 
Marcellin et  al., and the assumptions were used for the 
response rates for 48 weeks of therapy for Tenofovir [17]. 
The response data of Entecavir treatment for 48  weeks 
Fig. 1 Chronic hepatitis B treatment Markov model
Table 1 Transition rates between chronic hepatitis B and diseases [13]
Decompensated cirrhosis Hepatocellular cancer Transplantation Death (%)
Compensated cirrhosis 7.3 % 3.4 % 0.0 % 4.9
Decompensated cirrhosis – 3.4 % 20.0 % 19.0
Hepatocellular cancer – – 25.0 % 43.3
transplantation – – – 6.9
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were obtained from the study published by Arnold et al. 
[18]. The Lamivudine response data were obtained from 
the publications of Yuan et al. and Lai et al. [19, 20]. The 
Telbuvidin resistance data were obtained from the data of 
Lai et al. All assumptions and selected articles for mod-
eling were based on three experts’ opinions.
Cost calculation
The cumulative treatment cost was calculated by includ-
ing the costs of medicines, tests/follow ups, and compli-
cations. The costs paid by the Social Security Institution 
(SSI) on September 1, 2014 were taken for the calculation 
of the costs of medicines and tests/follow ups. The aver-
age annual costs of the treatment strategies included in 
the model according to the costs paid by the published 
figures are shown in Table 4. An annual 3 % discount rate 
was used for the calculation of the costs over the 40-year 
model process [21]. It was assumed that the discount rate 
covered the inflator and deflator effect.
The complication costs were taken from the study pub-
lished in 2009 [22, 23]. The data of 2014 were obtained 
by adapting the 2009 costs to a 3  % discount rate [21] 
(Table  5). The transition risks according to the plasma 
HBV DNA levels and the inter-transition of the compli-
cations and the mortality rates were taken from the pub-
lished studies in the application of the complication costs 
to the treatment strategies [11–17, 19, 24–26].
Calculation of clinical effectiveness
Years of life lost (YLL) was used for the clinical effective-
ness parameter. The life expectancy of healthy individu-
als according to the life expectancy at birth in Turkey 
was used for the response to therapy, and it was calcu-
lated again for each year in the model [27]. In the case 
Table 2 Response rates to chronic hepatitis B treatments [17–20]
Values are expressed as %
24th week TDF ETV 3TC LAM LdT TDF ETV 3TC LAM LdT
<300 84.8 84.8 73.0 71.0 80.0 48.9 37.0 34.0 32.0 45.0
300–104 9.7 9.7 15.0 20.0 15.0 32.5 40.0 26.0 31.0 31.0
104–105 2.7 2.7 3.6 2.7 1.5 8.9 11.0 12.0 11.1 7.2
105–106 0.2 0.2 1.5 1.1 0.6 0.8 1.0 5.0 4.6 3.0
>106 2.7 2.7 6.9 5.2 2.9 8.9 11.0 23.0 21.3 13.8
48th week
<300 93.2 93.3 75.6 71.4 88.3 76.1 69.1 39.8 40.4 60.0
300–104 4.2 4.1 12.5 18.4 8.0 19.1 24.7 18.2 28.1 21.5
104–105 1.6 1.6 5.1 7.5 3.3 3.4 4.4 11.7 18.1 13.8
105–106 0.3 0.3 2.0 0.8 0.1 0.5 0.6 9.3 4.1 1.4
>106 0.6 0.6 4.8 1.9 0.3 0.9 1.2 21.0 9.3 3.3
Table 3 Resistance to therapy for chronic Hepatitis B treatment [11–16]
Values are expressed as %
Years 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19
Resistance
 TDF 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 ETV 0.2 0.3 0.7 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 3TC 6.7 11.3 21.0 11.3 6.4 3.2 1.6 0.8 0.4 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 LtD/Hbe− 1.1 2.2 4.1 2.2 1.2 0.6 0.3 0.2 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 LtD/Hbe+ 5.0 6.3 11.6 6.3 3.5 1.8 0.9 0.4 0.2 0.1 0.1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
Cumulative resistance
 TDF 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0
 ETV 0.2 0.5 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2 1.2
 3TC 6.7 18.0 39.0 50.3 56.7 59.9 61.5 62.3 62.7 62.9 63.0 63.1 63.1 63.1 63.1 63.1 63.1 63.1 63.1
 LtD/Hbe− 1.1 3.3 7.4 9.6 10.8 11.4 11.8 11.9 12.0 12.0 12.1 12.1 12.1 12.1 12.1 12.1 12.1 12.1 12.1
 LtD/Hbe + 5.0 11.3 22.9 29.1 32.7 34.4 35.3 35.8 36.0 36.1 36.1 36.2 36.2 36.2 36.2 36.2 36.2 36.2 36.2
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of irresponsiveness to therapy, published complications 
and mortality transitions were used for the calculation of 
the YLL, and it was calculated again for each year in the 
model [11, 12, 14, 16, 19, 22–26].
Comparison of overall cost and clinical effectiveness
The calculated cumulative treatment cost and clinical 
effectiveness outcomes were compared according to 5, 
10, 20, 30, and 40 years of data calculated in the model.
Comparison of cost‑effectiveness
The incremental cost-effectiveness ratio (ICER) was used 
for the comparison of cost-effectiveness. The costs were 
sorted from minimum to maximum for the ICER calcula-
tion. An assessment was performed between the second 
leading minimum cost and the maximum cost. If a treat-
ment cost was lower than the next treatment cost and its 
effectiveness was higher, it was stated to be “superior,” 
and the assessment was performed with the next treat-
ment. If the effectiveness was high along with a high cost, 
the ICER formulation was applied as follows [27]:
The cumulative treatment cost (medicines, tests/fol-
low ups, and complications) was calculated at the end of 
40 years, which is the model year, and the YLL was used 
for the comparison of cost effectiveness.
Sensitivity analysis
The sensitivity analysis was conducted to show the impact 
of the change of the parameters on the cost-effectiveness 
ICER =
Total CostAnti-Viral 1− Total CostAnti-Viral 2
Clinical effectivenessAnti-Viral 1− Clinical EffectivenessAnti-Viral 2
ratio. A 25 % increase and decrease of the inputs method 
was used for the analysis [28].
Results and discussion
The treatment strategies were determined and analyzed 
for Tenofovir (TDF), Entecavir (ETV), switching to Ten-
ofovir from Entecavir (ETV-TDF), Lamivudine (3TC), 
switching to Tenofovir from Lamivudine (3TC-TDF), 
Telbivudine (LdT), and switching to Tenofovir from Tel-
bivudine (LdT-TDF).
Comparison of overall cost and clinical effectiveness
While the minimum years of life lost was found to be 0.22 
with TDF treatment for 5 years, the treatment cost was 
calculated as 12,169 TL. These values were identified as 
0.56  years and 7727 TL and 0.37  years and 12,770 TL, 
respectively, for the 3TC and LdT treatments.
The maximum years of life lost and the treatment cost 
with the 3TC treatment were identified as 1.60 years and 
18,813 TL, and, secondly, 0.89  years and 24,007 TL for 
the 3TC-TDF treatment for 10  years. The years of life 
lost and the treatment costs are 0.78  years and 26,848 
TL, 1.01 years and 27,295 TL, 0.57 years and 35,918 TL, 
0.57  years and 35,918 TL for the other treatment alter-
natives LdT-TDF, LdT, ETV, and ETV-TDF, respectively. 
The minimum years of life lost and cost are 0.54 year and 
35,821 TL for the TDF treatment for 10 years (Table 6).
The minimum years of life lost and the cost were deter-
mined as 1.21 years and 52,839 TL for the TDF treatment 
strategy for 20  years. The years of life lost and the cost 
for the other treatment strategies, ETV, ETV-TDF, LdT-
TDF, 3TC-TDF, LdT, and 3TC, are 1.25 years and 74,592 
TL, 1.25 years and 74,367 TL, 1.77 years and 58,542 TL, 
1.91 years and 54,785 TL, 2.37 years and 61,448 TL, and 
3.81 years and 49,974 TL, respectively.
Over a 30-year period, the TDF treatment was found to 
have the minimum years of life lost (1.73 years) and the 
minimum cost (84,149 TL). The years of life lost and the 
treatment costs are 1.79 years and 116,425 TL for ETV, 
1.79 years and 116,074 TL for ETV-TDF, 5.50 years and 
92,666 TL for 3TC, 2.70  years and 90,517 TL for 3TC-
TDF, 3.44 years and 102,458 TL for LdT, and 2.56 years 
and 95.357 T for LdT-TDF (Table 6).
Table 4 Treatment strategies for chronic hepatitis B in Turkey and the annual treatment costs
Medicines Dose Unit Dose (mg/tablet) Package (tablet/box) The average annual public
Cost of treatment (TL)
3TC 100 mg/day 100 28 839.94
ETV 0.5 mg/kg/day 0.5 30 3497.53
TDF 300 mg/day 300 30 2236.42
LdT 600 mg/day 600 28 2033.61
Table 5 The average annual costs of  disease conditions 
in Turkey
a 2014 costs were calculated by using 3 % reduction ratio according to 2009
Disease states Original costs (TL/year)
Year 2009 (TL) 2014a (TL)
Compensated cirrhosis 6778 7857
Decompensated cirrhosis 7573 8780
Hepatocellular carcinoma 31,044 35,989
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When the results of the 40-year period were ana-
lyzed, the years of life lost and costs are 2.06  years and 
119,604 TL, 2.13  years and 162,115 TL, 2.13  years and 
161,642 TL, 6.52  years and 147,245 TL, 3.20  years and 
132,157 TL, 4.10  years and 151,059 TL, and 3.05  years 
and 138,182 TL for TDF, ETV, ETV-TDF, 3TC, 3TC-TDF, 
LdT, and LdT-TDF, respectively (Table 6).
Comparison of cost‑effectiveness
According to the 40-year treatment model designed for 
an incremental cost-effectiveness comparison, the TDF 
treatment dominated the alternative treatment strategies, 
as it provided the minimum total cost and the minimum 
years of life lost. In other words, TDF was determined to 
be the most cost-effective treatment strategy compared 
to the other treatment strategies (Table 7).
In Table  6, the minimum treatment cost belongs to 
TDF with 119,604 TL in the total cost and drug cost 
comparison. The drug cost is 84,885 TL for the TDF 
treatment. The total treatment cost is 147,244 TL, and 
the drug cost is 28,151 TL for the 3TC treatment.
Sensitivity analysis
The sensitivity analysis was conducted for 25  % varying 
for each parameters. The most effective parameter for 
cost-effectiveness was observed as a virologic respond.
In all scenarios of the sensitivity analysis, it was shown 
that TDF has the lowest cost and the highest effective-
ness. Based on these results, TDF dominated all options 
in all scenarios (Tables 8, 9).
Conclusions
Currently, CHB treatment has achieved positive results 
regarding a high virologic response and a low resistance 
[4]. All published current guidelines recommend Tenofo-
vir and Entecavir as the first drug for CHB treatment.
Table 6 Years of life lost and treatment costs for each 10 years per capita
Treatments Year 10 Year 20 Year 30 Year 40
YLL Total cost (TL) YLL Total cost (TL) YLL Total cost (TL) YLL Total cost (TL)
TDF 0.54 24,948 1.21 52,839 1.73 84,149 2.06 119,604
3TC-TDF 0.89 24,007 1.91 54,785 2.70 90,517 3.20 132,157
LdT-TDF 0.78 26,848 1.77 58,542 2.56 95,357 3.05 138,182
3TC 1.60 18,813 3.81 49,974 5.50 92,666 6.52 147,245
LdT 1.01 27,295 2.37 61,448 3.44 102,458 4.10 151,059
ETV-TDF 0.57 35,821 1.25 74,366 1.79 116,074 2.13 161,642
ETV 0.57 35,918 1.25 74,592 1.79 116,425 2.13 162,115
Table 7 Incremental cost effectiveness analysis of chronic hepatitis B treatments
Calculations were done according to the constructed 40-year treatment model
Treatments Total cost (TL) YLL Cost difference (TL) Year difference ICER
TDF 119,604 2.06
ETV-TDF 161,642 2.13 42,037 0.07 Dominated
ETV 162,115 2.13 42,511 0.07 Dominated
LdT-TDF 138,182 3.05 18,577 0.99 Dominated
3TC-TDF 132,157 3.20 12,552 1.14 Dominated
LdT 151,059 4.10 31,455 2.04 Dominated
3TC 147,245 6.52 27,640 4.56 Dominated
Table 8 25 % varying impact on TDF outcomes
Age HBeAg (−)  
rate (%)
TDF: virologic response  
48th week in HBeAg (−) (%)
TDF: virologic response  
48th week in HBeAg (+) (%)
TDF annual 
drug cost (TL)
Base case 40 70 93.2 76.1 2236
25 % increase 50 88 100.0 95.2 2796
25 % decrease 30 53 69.9 57.1 1677
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Table 9 Sensitivity analysis results for the impact of each parameter on cost-effectiveness
Parameter Change New value Total  
cost (TL)




Age = 50 years 50 TDF 119,604 1.302
ETV-TDF 161,642 1.347 42,037 0.045
ETV 162,115 1.347 42,511 0.046
LdT-TDF 138,182 1.923 18,577 0.622
3TC-TDF 132,157 2.028 12,552 0.726
LdT 151,059 2.581 31,455 1.280
3TC 147,245 4.109 27,640 2.807
TDF 119,604 2.987
ETV-TDF 161,642 3.088 42,037 0.101
ETV 162,115 3.089 42,511 0.102
Age = 30 years 30 LdT-TDF 138,182 4.429 18,577 1.442
3TC-TDF 132,157 4.621 12,552 1.634
LdT 151,059 5.954 31,455 2.967
3TC 147,245 9.453 27,640 6.465
TDF 119,411 2.025
ETV-TDF 161,353 2.079 41,943 0.054
ETV 161,826 2.079 42,416 0.055
HBeAg (−) rate 25 % increase 88 % LdT-TDF 132,215 2.656 12,804 0.631
3TC-TDF 127,731 2.907 8320 0.882
LdT 137,643 3.152 18,233 1.128
3TC 128,004 5.124 8593 3.099
TDF 119,798 2.096
ETV-TDF 161,930 2.183 42,132 0.087
ETV 162,404 2.183 42,606 0.088
HBeAg (−) rate 25 % decrease 53 % LdT-TDF 144,149 3.445 24,351 1.349
3TC-TDF 136,582 3.487 16,784 1.391
LdT 164,475 5.045 44,677 2.949
3TC 166,486 7.907 46,688 5.811
TDF 119,573 2.055
ETV-TDF 161,642 2.131 42,068 0.076
ETV 162,115 2.131 42,542 0.076
TDF: virologic response 48th week 
in HBeAg (−)
25 % increase 100.0 % LdT-TDF 138,176 3.049 18,603 0.994
3TC-TDF 132,148 3.196 12,574 1.140
LdT 151,059 4.099 31,486 2.043
3TC 147,245 6.515 27,672 4.460
TDF 119,711 2.078
ETV-TDF 161,642 2.131 41,931 0.053
ETV 162,115 2.131 42,404 0.053
TDF: Virologic response 48th week 
in HBeAg (−)
25 % decrease 69.9 % LdT-TDF 138,202 3.054 18,491 0.976
3TC-TDF 132,186 3.202 12,475 1.124
LdT 151,059 4.099 31,348 2.021
3TC 147,245 6.515 27,534 4.437
TDF 119,538 2.049
ETV-TDF 161,642 2.131 42,103 0.082
ETV 162,115 2.131 42,577 0.082
TDF: Virologic response 48th week 
in HBeAg (+)
25 % increase 95.2 % LdT-TDF 138,153 3.044 18,614 0.996
Page 8 of 10Kockaya et al. Cost Eff Resour Alloc  (2015) 13:21 
In the study conducted in Taiwan and published by 
Veenstra et al. [29], a life-long Markov model was used, 
and Entecavir monotherapy was found to be more cost-
effective compared to Lamivudine and Adefovir diso-
proxil combination treatments. In this analysis, Tenofovir 
monotherapy was found to be the most cost-effective 
treatment during the first 5 years, the first 10 years, for 
30 years, and for 40-year life spans, which is similar to the 
results of the life span assessment.
In a disease burden study about HBV conducted in 
Vietnam and published in 2008, the average annual 
HBV disease cost was determined as $450.35 for this 
country [30]. In research conducted in China and pub-
lished in 2013, the cost of CHB was found to be $4.136 
[31]. In another study conducted in the US, the average 
life span cost per capita of HBV was estimated as $2.667 
[32]. In a cost analysis of immigrants using the 2006 
data in Canada, the treatment costs of Entecavir, Teno-
fovir, Lamivudine, and pegylated interferon (48  weeks) 
were determined as $6.504, $5.032, $1.516, and $10.185, 
respectively [33].
In a hospital-based CHB and CHC treatment cost 
study evaluating 284 patients in the Denizli province in 
Turkey, it was found that the treatment cost and total 
cost were higher with the Entecavir treatment compared 
to the Tenofovir and Lamivudine treatments. PEG Int-2a 
and 2b treatments had a higher cost than Lamivudine, 
Entecavir, Tenofovir treatments, and no treatment [34].
In an analysis including the US, Germany, and some 
Asian countries conducted by Lui et  al. [35], the most 
cost-effective treatment was found to be Entecavir and 
Tenofovir monotherapies among switching from Telbi-
vudine and Lamivudine monotherapies to Tenofovir and 
Entecavir treatments.
In other studies, Tenofovir was reported to be the most 
cost-effective treatment among Tenofovir, Entecavir, Tel-
bivudine, and Adefovir treatments [35, 36].
There are limitations of this study as assumptions. All 
assumptions and articles that were used in the study were 
taken from three experts’ opinions.
In the model presented in this study used for the cost-
effectiveness analysis of CHB treatments, Tenofovir was 
Tenofovir dominates all comparisons in all scenarios
Table 9 continued
Parameter Change New value Total  
cost (TL)




3TC-TDF 132,118 3.190 12,580 1.141
LdT 151,059 4.099 31,521 2.050
3TC 147,245 6.515 27,707 4.467
TDF 119,671 2.072
ETV-TDF 161,642 2.131 41,971 0.059
ETV 162,115 2.131 42,444 0.060
TDF: Virologic response 48th week 
in HBeAg (+)
25 % decrease 57.1 % LdT-TDF 138,211 3.056 18,540 0.985
3TC-TDF 132,195 3.204 12,524 1.133
LdT 151,059 4.099 31,388 2.027
3TC 147,245 6.515 27,574 4.444
TDF 140,826 2.060
ETV-TDF 161,879 2.131 1053 0.070
ETV 162,115 2.131 1289 0.071
TDF annual drug cost 25 % decrease 2796 TL LdT-TDF 144,943 3.050 4117 0.990
3TC-TDF 147,174 3.197 6348 1.137
LdT 151,059 4.099 0233 2.038
3TC 147,245 6.515 6419 4.455
TDF 98,383 2.060
ETV-TDF 161,405 2.131 63,022 0.070
ETV 162,115 2.131 63,732 0.071
TDF annual drug cost 25 % decrease 1677 TL LdT-TDF 131,421 3.050 33,038 0.990
3TC-TDF 117,139 3.197 18,756 1.137
LdT 151,059 4.099 52,676 2.038
3TC 147,245 6.515 48,862 4.455
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found to be one of the cost-effective methods in com-
parison with other treatment strategies at different time 
intervals. In addition to this achievement, Tenofovir has 
been shown to reduce the cumulative treatment cost 
in the first line of CHB treatment when compared to a 
40-year cumulative treatment cost.
In addition, the sensitivity analysis showed that the 
most effective parameter is the virologic respond; how-
ever, TDF had the lowest cost and the highest effective-
ness rates as a cost-effective option in all scenarios.
In conclusion, it could be stated that Tenofovir provides 
cost-effective results regarding public costs and sustain-
able health financing by being included in the reimburse-
ment for the first line of CHB treatment both in less years 
of life lost and the reduced cumulative treatment cost.
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